Borealis Biosciences raised $150 million in Series A financing led by Versant Ventures and Novartis to develop next-generation RNA therapeutics for kidney diseases.

Aug 22, 2024•over 1 year ago

Amount Raised

$150 Million

Round Type

series a

VancouverTherapeuticsBiotechnologyHealth Care

Investors

Novartis AgVersant Ventures

Description

Borealis Biosciences emerged from stealth today with $150 million in combined Series A financing from Versant Ventures and Novartis AG. The funding will support the company's mission to address major unmet needs for patients with kidney diseases through RNA therapeutics.

Company Information

Company

Borealis Biosciences

Location

Vancouver, British Columbia, Canada

About

Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends